Merck (MRK) Tax Provisions (2009 - 2026)
Merck (MRK) posted quarterly Tax Provisions of $709.0 million for Q1 2026, down 13.33% year-over-year from $818.0 million in Q1 2025, and up 54.8% quarter-over-quarter from $458.0 million in Q4 2025.
Merck (MRK) Tax Provisions (2009 - 2026) Analysis & Trends
Merck (MRK) has reported Tax Provisions for 18 consecutive years, with $709.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Tax Provisions fell 13.33% year-over-year to $709.0 million; the TTM figure through Mar 2026 stood at $2.7 billion (down 0.81% YoY), while the FY2025 annual figure was $2.8 billion, changed 0.04% from the prior year.
- Tax Provisions improved to $709.0 million in Q1 2026 per MRK's latest filing, from $458.0 million in the prior quarter.
- Across five years, Tax Provisions topped out at $958.0 million in Q3 2025 and bottomed at -$820.0 million in Q4 2023.
- Historically, Tax Provisions has averaged $573.3 million across 5 years, with a median of $571.0 million in 2025.
- Annual changes were most pronounced in 2022 — Tax Provisions surged 482.35% — and 2023, when it slumped 265.66%.
- Merck's Tax Provisions stood at $495.0 million in 2022, then plunged by 265.66% to -$820.0 million in 2023, then soared by 151.95% to $426.0 million in 2024, then grew by 7.51% to $458.0 million in 2025, then jumped by 54.8% to $709.0 million in 2026.
- Business Quant data shows MRK's Tax Provisions at $709.0 million in Q1 2026, $458.0 million in Q4 2025, and $958.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 1.21 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 662.00 Mn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 654.00 Mn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 1.01 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 291.00 Mn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 393.00 Mn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 242.00 Mn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | -407.00 Mn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 266.99 Mn |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | -524.23 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 654.00 Mn |
| Mar 31, 2026 | 709.00 Mn |
| Dec 31, 2025 | 458.00 Mn |
| Sep 30, 2025 | 958.00 Mn |
| Jun 30, 2025 | 571.00 Mn |
| Mar 31, 2025 | 818.00 Mn |
| Dec 31, 2024 | 426.00 Mn |
| Sep 30, 2024 | 929.00 Mn |
| Jun 30, 2024 | 545.00 Mn |
| Mar 31, 2024 | 903.00 Mn |
| Dec 31, 2023 | -820.00 Mn |
| Sep 30, 2023 | 870.00 Mn |
| Jun 30, 2023 | 637.00 Mn |
| Mar 31, 2023 | 825.00 Mn |
| Dec 31, 2022 | 495.00 Mn |
| Sep 30, 2022 | 330.00 Mn |
| Jun 30, 2022 | 538.00 Mn |
| Mar 31, 2022 | 554.00 Mn |
| Dec 31, 2021 | 85.00 Mn |
| Sep 30, 2021 | 695.00 Mn |